Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | -0.59% | +1.35% | +18.59% |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
May. 13 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
Evolution of the average Target Price on Merck & Co., Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Merck & Co., Inc.
Redburn Atlantic | |
Wolfe Research | |
Morgan Stanley | |
Guggenheim | |
Deutsche Bank Securities | |
JPMorgan Chase | |
Wells Fargo Securities | |
Goldman Sachs | |
Leerink Partners | |
Truist Securities | |
Jefferies & Co. | |
Cantor Fitzgerald | |
BMO Capital | |
Zacks Investment Research | |
Berenberg Bank | |
Societe Generale | |
UBS | |
Barclays | |
BofA Securities | |
TD Cowen | |
HSBC | |
Atlantic Equities | |
Citigroup | |
Credit Suisse | |
SVB Securities LLC | |
Daiwa Securities | |
Cowen | |
SVB Leerink | |
Argus | |
RBC Capital Markets | |
RBC | Randall Stanicky |
JPMORGAN |
EPS Revisions
- Stock Market
- Equities
- MRK Stock
- Consensus Merck & Co., Inc.